Serum folate receptor α (sFR) in ovarian cancer diagnosis and surveillance

Collectively, our data demonstrate that sFR could improve diagnostic accuracy. Additionally, the monitoring of sFR and CA125 (and potentially other markers) could conceivably improve cancer surveillance, affecting prognosis. We have initiated a prospective clinical trial studying sFR induction in the initial diagnosis and surveillance of OVCA as a means to abrogate potential limitations of this biomarker.

Abstract

Novelty and Impact Statement: Our findings suggest that soluble folate receptor (sFR) could be used in both the initial diagnosis and surveillance of patients with ovarian cancer. Our cohort constitutes one of the largest comparison groups for sFR analyzed so far. We have defined the background level of sFR using healthy volunteers. This is also the first study to prospectively follow patients in the surveillance setting to concurrently identify differential changes in tumor markers CA‐125 and sFR.

http://bit.ly/2tmbpiY